



VGX Licenses Additional DNA Vaccines Technology from the University of Pennsylvania

Blue Bell, PA – June 23, 2008 –

VGX Pharmaceuticals Inc. (VGX) announced today that the Company has amended its license agreement with the University of Pennsylvania adding technologies for its novel DNA Vaccines and Therapeutics. The underlying technology was developed in the laboratory of Professor David B. Weiner at the University of Pennsylvania. Professor Weiner is a pioneer in the field of DNA vaccines.

This new amendment adds novel adjuvants to enhance the effectiveness of DNA vaccines. Under the terms of the original license agreement completed last year, the Company obtained exclusive worldwide rights to develop a number of DNA plasmids and constructs with the potential for the treatment and/or prevention of HIV, HCV, HPV and influenza. VGX's genetic adjuvant program now includes one for optimized interleukin-15 (IL-15), which is already in Phase I clinical trials to improve the immune responses to PENNVAX™-B HIV vaccines.

"We are pleased to have access to these additional technologies, which further expand our development pipeline of a new generation of DNA-based therapies and vaccines for use in humans," said Dr. J. Joseph Kim, President and CEO of VGX. "These additional genetic adjuvants will strengthen and complement our existing R&D programs."

Using its vertically integrated product development platform, VGX has taken three independent product programs from 'Bench to IND filing' within 12 months. In 2008 alone, the Company has filed INDs for a DNA therapeutic vaccine for cervical cancer (VGX-3100), a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia (VGX-3200), and a DNA preventative vaccine for avian influenza (VGX-3400).

Cautionary Factors That May Affect Future Results - Materials in this Web site contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation

of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, PENNVAX™-B for HIV infection, which is in 2 separate Phase I clinical trials, and VGX-1027 for inflammatory diseases, which is in Phase I clinical trials. In addition, the Company has filed INDs for VGX-3100, a DNA therapeutic vaccine for cervical cancer; VGX-3200, a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia; and VGX-3400, a DNA preventative vaccine for avian influenza. VGX has established a vertically-integrated DNA Vaccines and Therapies Platform with extensive capabilities including SynCon™ DNA-based product candidates, the CELLECTRA® delivery device, and efficient cGMP plasmid manufacturing. Vertical control over key aspects of product development has enabled the Company to consistently develop multiple product candidates, from bench-to-IND filing, within 1 year. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas
Senior Vice-President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com